Houston cardiology-focused tech platform exits to private equity, plans to scale

making moves

CardioOne, which built a physician enablement platform for independent cardiologists, has been acquired by WindRose Health Investors. Photo via cardioone.com

A Houston health tech startup founded only last year has exited to a New York private equity firm.

CardioOne, which built a physician enablement platform for independent cardiologists, has been acquired by WindRose Health Investors. The complete terms of the deal were not disclosed, but according to a WindRose news release, the firm will provide up to $100 million of additional capital to go toward supporting CardioOne's growth.

The fresh influx of capital will go toward expanding and enhancing existing service options. The CardioOne leadership team will continue to be at the helm of the startup.

"We are excited for the opportunity to partner with WindRose as CardioOne embarks on its next chapter of growth," Dr. Jasen Gundersen, CardioOne's CEO and co-founder, says in the release. "We believe that working with WindRose, which has a history of successfully partnering with companies to help navigate the transition to value-based care, will empower us to continue supporting independent cardiologists while developing additional solutions that maximize each practice's potential in the shift to VBC arrangements."

Last year, CardioOne raised an $8 million seed round and announced key partnerships at clinics in New Jersey, Florida, and Pennsylvania, in addition to existing relationships in Texas and Maryland. CardioOne also partnered with MedAxiom, an organizational performance solutions provider in the industry.

"CardioOne's unique, physician-aligned model meets the market where it is and positions the Company to take advantage of the growing desire among cardiologists to maintain their independence," Oliver Moses, managing partner with WindRose, adds. "We believe CardioOne delivers a compelling tech-enabled offering to the independent cardiology market and has significant growth potential as the Company builds upon its momentum in 2023. We are excited to join forces with Jasen and his team as they continue to build upon the differentiated platform they have created."

CardioOne has fresh funding and new partners, resulting in a five-state expansion. Photo via Getty Images

Houston heart health startup secures $8M in funding, announces new partnerships

cardiatric care

With fresh funding, a Houston-based health tech platform that's less than a year old has grown its United States footprint.

CardioOne, which has created a cardiology care delivery enablement platform that serves independent cardiologists, has closed an $8 million seed round of funding and secured three new partnerships. Axios and Crunchbase report that the round has closed, and CardioOne confirms the funding and new partnerships in a press release.

The company has three new partnerships with independent cardiology clinics in New Jersey, Florida, and Pennsylvania, Cardiac Associates of New Jersey, Twin Hearts LLC, and Corrieius Cardiology. The trio joins existing partner practices in Texas and Maryland.

In addition to joining forces with these practices, CardioOne has entered into a partnership with MedAxiom, which is described as being "the cardiovascular community’s premier source for organizational performance solutions," in the release.

“CardioOne is optimizing cardiology practice management and providing new options for independent cardiologists,” Joe Sasson, MedAxiom’s executive vice president of ventures and chief commercial officer, says in the news release. “With CardioOne, independent cardiology practices can access the scale and leverage typically reserved for large hospital groups and are empowered to grow through additional service lines, strong network relationships, and payor contracts, including value-based care arrangements.”

Dr. Jasen Gunderson, who's based in Denver, is the CEO and co-founder of CardioOne, which was founded last year. He explains the challenges of independent cardiologists, which includes inefficient revenue cycle tools, incomplete vendor management systems, and other tech-based and administrative obstacles — most of which CardioOne addresses.

“Inadequate and fragmented technology is at the root of many of the problems that independent cardiologists are facing today,” Gunderson says in the release. “CardioOne’s solution removes the heavy administrative burdens, empowering cardiologists to focus on their expertise and true passion – the practice of medicine without feeling forced into acquisition.”

CardioOne's mission is to continue to help cardiology practices maintain their independence while keeping up with demand, patient care, and business growth.

"Our independence and clinical autonomy has allowed our practice to provide more personalized care to our patients, but in a consolidating market... the resources and technology investments required to run a practice group today make staying independent more difficult than ever before,” Dr. John H. Lee of Cardiac Associates of North Jersey, says in the release. “CardioOne is a true collaborator, serving as an extension of our operations and allowing us to focus on doing what we love — caring for patients.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice to revolutionize lymphatic disease research and more news to know

Trending Topics

Editor's note: We're looking back at the five biggest innovation headlines from the second half of February 2026, which include exciting Rice research advancements and Apple doubling down on production in Houston. Below are the five most-read InnovationMap stories from Feb. 16-28, 2026.

1. Rice University lands $18M to revolutionize lymphatic disease detection

Rice University scientists are pioneering two technologies to better diagnose and treat complex lymphatic anomalies. Photo via Getty Images.

An arm of the U.S. Department of Health and Human Services has awarded $18 million to scientists at Rice University for research that has the potential to revolutionize how lymphatic diseases are detected and help increase survivability. Continue reading.

2. Tech giant Apple doubles down on Houston with new production facility

Apple doubles down on Houston with new production facility, training centerPhoto courtesy Apple.

Tech giant Apple announced that it will double the size of its Houston manufacturing footprint as it brings production of its Mac mini to the U.S. for the first time. The company plans to begin production of its compact desktop computer at a new factory at Apple’s Houston manufacturing site later this year. The move is expected to create thousands of jobs in the Houston area, according to Apple. Continue reading.

3. Houston startup debuts new drone for first responders

Paladin Drones has revealed its next-gen emergency response drone, Knighthawk 2.0. Photo courtesy Paladin.

Houston-based Paladin Drones has debuted Knighthawk 2.0, its new autonomous, first-responder drone. The drone aims to strengthen emergency response and protect first responders, the company said in a news release. “We’re excited to launch Knighthawk 2.0 to help build safer cities and give any city across the world less than a 70-second response time for any emergency,” said Divyaditya Shrivastava, CEO of Paladin. Continue reading.

4. XSpace adds 3 Houston partners to fuel national expansion

XSpace, an innovative commercial real estate company, has partnered with three Houston firms to help grow its footprint. Rendering via xspacegroup.com

Texas-based XSpace Group has brought onboard three partners from the Houston area to ramp up the company’s national expansion. The new partners of XSpace, which sells high-end multi-use commercial condos, are KDW, Pyek Financial and Welcome Wilson Jr. Houston-based KDW is a design-build real estate developer, Katy-based Pyek offers fractional CFO services and Wilson is president and CEO of Welcome Group, a Houston real estate development firm. Continue reading.

5. Houston doctor wins NIH grant to test virtual reality for ICU delirium

Dr. Hina Faisal will test the effects of VR games on patients coming out the ICU, thanks to a recent NIH grant. Photo via Getty Images.

Think of it like a reverse version of The Matrix. A person wakes up in a hospital bed and gets plugged into a virtual reality game world in order to heal. While it may sound far-fetched, Dr. Hina Faisal, a Houston Methodist critical care specialist in the Department of Surgery, was recently awarded a $242,000 grant from the National Institute of Health to test the effects of VR games on patients coming out of major surgery in the intensive care unit (ICU). Continue reading.

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

View All Listings